Navigation Links
Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
Date:5/24/2012

SAN DIEGO, May 24, 2012 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing and commercializing targeted rescue therapies for patients in acute ischemic crisis, today announced that it recently received $50 million in additional equity funding from existing investor, Leucadia National Corporation. This funding was made upon the exercise of Series G preferred stock warrants previously held by Leucadia and brings the total funding raised by the company since inception to more than $280 million.

(Logo: http://photos.prnewswire.com/prnh/20120524/LA12228LOGO)

This funding followed an independent Data Monitoring Committee (DMC) review of safety data from the first 122 patients enrolled in the Phase 2b trauma study involving MP4OX, Sangart's novel oxygen therapeutic agent (OTA) developed to perfuse and oxygenate tissues at risk for ischemia in patients experiencing hemorrhagic shock. After evaluating the data, the DMC unanimously recommended that the study should continue without any modification.

"We are encouraged by this level of support from our existing investors, who recognize the clinical potential of our products," said Brian O'Callaghan, President and CEO of Sangart. "This funding will allow us to continue advancing the development of our medicines and get them as quickly as possible to patients in need. We continue to see promise in our unique MP4 gas-delivery platform, focused on developing therapies for patients in crisis who are experiencing ischemia and organ dysfunction as a result of hemorrhagic shock injury or a vaso-occlusive crisis associated with sickle cell disease."

The funds will be used to advance the development of the MP4OX product in severe traumatic hemorrhagic shock and the MP4CO product in sickle cell disease.  

About MP4
Sangart's unique MP4 gas-delivery platform is being used to develop therapies for patients in crisis who are experiencing ischemia (oxygen deprivation of tissues) and organ dysfunction as a result of hemorrhagic shock injury or a vaso-occlusive crisis associated with sickle cell disease.

About Sangart
Sangart is a global biopharmaceutical company dedicated to developing and commercializing targeted rescue therapies for patients in acute ischemic crisis. Sangart's therapies are designed to help patients with medical conditions that cause ischemia, such as hemorrhagic shock and sickle cell disease.

To learn more about Sangart, please visit the company's website at www.sangart.com.

Media Contact:
Vivian Cabral
Edelman Public Relations
Office: 323-202-1032
vivian.cabral@edelman.com

 


'/>"/>
SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
2. Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients
3. Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease
4. Sangart, Inc. Completes Series F Funding Round
5. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
6. Cerecor Raises $22 Million Series A Financing
7. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
8. Cowen Healthcare Royalty Partners Raises $1 Billion
9. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
10. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
11. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... February 23, 2017 , ... David Nolte, PhD ... Reception at Purdue Research Park of West Lafayette, Indiana. , The ... outstanding contributions to, and success with, commercializing discoveries from Purdue research. “This award ...
(Date:2/23/2017)... -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological ... Linda Marbán, Ph.D, president and chief executive officer, is scheduled ... Cowen and Company 37th Annual Health Care Conference Tuesday, ... MA 29th Annual ROTH Conference ... ET) Dana Point, CA ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one members ... named Fellows of the Society this year, the Fellows Committee has announced. The ... of optics, photonics, and imaging as well as their service to the Society ...
Breaking Biology Technology:
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/26/2017)... 2017  Crossmatch, a leading provider of security and ... at combatting fraud, waste and abuse in assistance operations ... Action on Disaster Relief conference in Panama ... agencies and foreign assistance organizations throughout Latin ... are a largely unacknowledged problem in the foreign assistance ...
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
Breaking Biology News(10 mins):